Dr. Mo Jain
Founder & CEO at Sapient
Bio Info
Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, biomedicine, engineering, computational biology, and mass spectrometry-based metabolomics. He formed and managed Jain Laboratory at the University of California San Diego, where he guided a multi-disciplinary research team to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe the non-genetic landscape of disease across large-scale human studies.
By 2021, Dr. Jain founded Sapient, a discovery metabolomics lab dedicated to accelerating research and sponsor drug programs through rapid, large-scale small molecule biomarker profiling. Combining rLC-MS, an expert data science team, and large-scale human biology datasets, Sapient enables rapid identification of circulating biomarkers of health, disease, and drug responsiveness that are needed to effectively align patients, diseases, and specific therapies.
Booking Dr. Jain would give biopharma professionals working in biomarkers, translational science, precision medicine, and therapeutic areas targeting complex diseases a new perspective on how small molecule biomarkers can applied to advance their drug programs and personalize therapy, and how next-generation technology is enabling their discovery at an entirely new scale – to accelerate drug discovery, transform therapy, and better patient outcomes. Book Dr. Jain now!
Videos
On the Mark: Identifying Non-Invasive Biomarkers of Target Engagement
In this session, Dr. Mohit Jain, Founder and CEO of Sapient, discusses methods for the rapid discovery of small molecule biomarkers of target engagement, leveraging integration of next generation mass spectrometry, genomics, and experimental systems.
What’s Next in Precision Medicine? Small Molecule Biomarkers to Personalize Diagnostics & Therapies
In this webinar, Sapient's Dr. Mo Jain discusses how the mapping of small molecule biomarkers in blood delivers complementary information relative to traditional DNA and protein biomarkers, which can be used in drug development programs to predict disease risk, identify patient subgroups, and create more specific, efficacious therapies aligned with a patient’s unique disease biology.
Previous Interviews
New Matter: Inside the Minds of SLAS Scientists
Accelerating Human Discovery | A Lesson in Small Molecule Biomarkers with Mo Jain, M.D., Ph.D.
Topic Suggestions
Disruptive tech vs traditional methods in biopharma - A new scale of discovery
Today's role of biomarkers in advancing precision medicine
The pitfalls of drug development and how they should be improved
How to better personalize disease prediction, diagnostics, & therapies
New methods for biomarker discovery, validation, & translation for clinical impact
Specificity at scale - Therapy transformation & drug discovery acceleration
3 reasons genetics alone are not enough to personalize medicine
Next-generation discovery technology – How much more can we find?
Book Speaker Now
Click the button below to reach out to us and let us know!
2 Extra Reasons To Book...
Expert Guests Matter
Our guests have experience appearing on podcasts,
so you don't need to coach them.
Eager to Share
Our guests see the value in appearing on your show,
and they are ready to share their experience
with their audience - and the world!